Amgen Inc. (AMGN) Financials
PeriodQ2 FY2026
Published
Amgen reported total revenues of $10.05 billion for Q2 FY2026, the quarter ended June 30, 2026, up 9.5% from a year earlier, as volume growth in products including Repatha, EVENITY and UPLIZNA outweighed biosimilar erosion of Prolia and XGEVA. Net income was $2.38 billion, up 65.9%, and diluted earnings per share were $4.37, up 64.9%. Operating income rose to $3.51 billion, up 32.3%, as lower amortization of acquired intangible assets and smaller Horizon inventory step-up charges reduced cost of sales, and a smaller unrealized loss on Amgen's stake in BeOne Medicines added to the gain in net income.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $10,054,000,000 | up 9.5% |
| Net income | $2,375,000,000 | up 65.9% |
| Diluted EPS | $4.37 | up 64.9% |
| Operating income | $3,514,000,000 | up 32.3% |
Company details
| Name | Amgen Inc |
|---|---|
| Ticker | AMGN |
| CIK | 0000318154 |
| Exchange | Nasdaq |
| State | California |
| Incorporation | Delaware |
| SIC | 2836 |
| Office | Life Sciences |
| Industry | Biological Products, (No Diagnostic Substances) |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0000318154-26-000126 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-11-04 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Amgen Q2 FY2026
How much revenue did Amgen report in Q2 FY2026?
Amgen reported total revenues of $10.05 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 9.5% from $9.18 billion in the same quarter a year earlier.
What was Amgen's net income in Q2 FY2026?
Amgen's net income was $2.38 billion in Q2 FY2026, the quarter ended June 30, 2026, up 65.9% from $1.43 billion in the same quarter a year earlier.
What were Amgen's earnings per share in Q2 FY2026?
Amgen earned $4.37 per diluted share in Q2 FY2026, the quarter ended June 30, 2026, up 64.9% from $2.65 in the same quarter a year earlier.
Why did Amgen's profit grow faster than its revenue in Q2 FY2026?
Amgen's operating income rose to $3.51 billion in Q2 FY2026, up 32.3% from $2.66 billion a year earlier, because revenue grew while lower amortization of acquired intangible assets and smaller Horizon inventory step-up charges reduced cost of sales. Net income also benefited from a smaller unrealized loss on Amgen's stake in BeOne Medicines than in the same quarter a year earlier.
Where can I get Amgen Inc. (AMGN) financial data in machine-readable form?
Ticker Scout publishes Amgen Inc.'s financial statements as JSON at https://tickerscout.ai/amgn/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/amgn/narrative.md and https://tickerscout.ai/amgn/events.md. Amgen Inc.'s SEC CIK is 0000318154. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Amgen Inc. (AMGN) next file with the SEC?
Amgen Inc. (AMGN) is expected to file its next Form 10-Q with the SEC on or around November 4, 2026. That date is a projection rather than a company-announced date: it is derived from Amgen Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000318154-26-000126.
Related companies
How this page was built
This page was built from Amgen Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.